Description
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a prescription medication used to reverse the anticoagulant effect of apixaban and rivaroxaban in patients who experience life-threatening or uncontrolled bleeding. The medication is administered by intravenous injection.
Uses:
Andexxa is used to reverse the anticoagulant effect of the medications apixaban and rivaroxaban in patients experiencing life-threatening or uncontrolled bleeding. Apixaban and rivaroxaban are commonly used as anticoagulants to prevent blood clots. Andexxa works by binding to apixaban and rivaroxaban and neutralizing their anticoagulant effects.
Storage Conditions:
Andexxa should be stored in a refrigerator at 2°C to 8°C in its original packaging. The medication is stable for up to 24 months when stored in a refrigerator.
Mechanism of Action:
Andexxa is a recombinant protein that binds to apixaban and rivaroxaban and neutralizes their anticoagulant effect. Apixaban and rivaroxaban are anticoagulant medications that inhibit the clotting activity of the enzyme factor Xa. Andexxa binds to apixaban and rivaroxaban, which allows factor Xa to form blood clots.
HOW TO USE:
Andexxa is administered by intravenous injection under the supervision of a healthcare professional. The recommended dosage is 400 mg over the course of two bolus injections, followed by a two-hour infusion at a rate of 4 mg/min. The dosage may be adjusted based on the patient’s weight and the dose of apixaban or rivaroxaban that was taken.
Precautions:
• Andexxa is not indicated for the reversal of anticoagulant effects of any other medications besides apixaban and rivaroxaban.
• The most common adverse reactions reported with Andexxa use include urinary tract infections, pneumonia, and infusion-related reactions.
• Patients should inform their healthcare provider of all medications, supplements, or herbal products they are taking before starting treatment with Andexxa.
Drug Interactions:
Andexxa has not been studied in patients taking anticoagulant medications other than apixaban and rivaroxaban. However, Andexxa may interact with other medications that affect blood clotting. Patients should inform their healthcare provider of all medications they are taking before starting treatment with Andexxa.
Contraindications:
• Andexxa should not be used in patients with a history of hypersensitivity to Andexxa.
• The safety and efficacy of Andexxa have not been established in patients with hepatic impairment or end-stage renal disease.
Overdose:
There is no specific treatment for Andexxa overdose; patients who have received an overdose should be monitored for adverse reactions.
Adverse Reactions:
The most common adverse reactions reported with the use of Andexxa include urinary tract infections, pneumonia, and infusion-related reactions. Patients should inform their healthcare provider of any unusual or unexpected reactions while using Andexxa.
In conclusion, Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a medication used to reverse the anticoagulant effect of apixaban and rivaroxaban in patients who experience life-threatening or uncontrolled bleeding. The medication is administered by intravenous injection and works by binding to apixaban and rivaroxaban and neutralizing their anticoagulant effects. Andexxa should be stored in the refrigerator at 2°C to 8°C and is stable for up to 24 months. Patients with a history of hypersensitivity to Andexxa should not receive the medication, and the safety and efficacy of Andexxa have not been established in patients with hepatic impairment or end-stage renal disease. Patients taking other medications before treatment should inform their healthcare provider. While Andexxa has common adverse reactions such as urinary tract infections, pneumonia, and infusion-related reactions, patients should still consult their healthcare provider if they have any unusual reactions.
Reviews
There are no reviews yet.